評論
打印
A new study suggests we need to rethink diabetes treatment because of the rising cost of insulin.
一項(xiàng)新的研究表明，我們需要重新考慮糖尿病的治療，因?yàn)橐葝u素成本的增長。
The increasing costs have been noted in recent years, with some blaming a lack of "healthy" competition.
近年來人們注意到了日益增長的成本，一些人指責(zé)缺乏“健康”的競爭。
The interesting thing about the insulin market is there's really only three companies in the insulin market. So it's a very small number of companies. There's no generics, and the prices just seem to go up for these drugs in tandem.
關(guān)于胰島素市場有趣的事是，胰島素市場上真正只有三家公司。所以公司的數(shù)量非常小。無非專利藥物，而且這些藥物價格似乎相繼上漲。
The study, published in JAMA, looked at insulin prices from 2002 to 2013. Since 2002, the cost of insulin increased by almost 200 percent — an increase made even more significant by findings that showed the amount of insulin being used per patient also increased.
該研究發(fā)表在美國醫(yī)學(xué)會雜志，關(guān)注2002年到2013年胰島素的價格。自2002年，胰島素的價格增加了近百分之200，調(diào)查結(jié)果顯示每名患者使用的胰島素量也有所增加。
Medical Xpress suggests the increase in doses could be due to increases in obesity in that time period, and new national recommendations stressing lower sugar intake.
醫(yī)學(xué)快訊建議，使用劑量的增加可能是由于這段時間內(nèi)肥胖的增加，以及新的國家建議強(qiáng)調(diào)低糖攝入。
Researchers predicted "the mean price of insulin is unlikely to decline as a result of generic competition because of the stringent regulations and substantial costs of bringing biosimilar insulins to market."
研究人員預(yù)測，“胰島素的平均價格不太可能由于仿制藥的競爭下降，因?yàn)閲?yán)格的法規(guī)以及引進(jìn)生物仿制胰島素進(jìn)入市場的大量成本。
譯文屬可可原創(chuàng)，僅供學(xué)習(xí)交流使用，未經(jīng)許可請勿轉(zhuǎn)載。
